Here are relevant reports on : parkinsons-disease-market
-
Foregut Surgery Devices Market by Product (Endoscope, Hand Instrument), Procedure (Complex Esophagogastric Surgery, Per-Oral Endoscopic Myotomy), Disease (Reflex Disease, Hiatal Hernias), End User (Hospitals) - Global Forecast to 2022
The global foregut surgery devices market is expected to reach USD 699.7 Million by 2023 from USD 485.1 Million in 2018, growing at a CAGR of 7.6% from 2018 to 2023. Rising incidence and prevalence of diseases, technological advancements, rising number of foregut surgical procedure some of the major driving factors driving the growth of the global foregut surgery devices market. However, the high cost of surgery hindering the growth of this market to a certain extent.
- Published: July 2026
- Price: $ 4950
- TOC Available:
-
North America Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)-Forecast to 2030
The North America biomarkers Market, valued at US$23.35 billion in 2024, stood at US$25.13 billion in 2025 and is projected to advance at a resilient CAGR of 11.0% from 2025 to 2030, culminating in a forecasted valuation of US$45.25 billion by the end of the period. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Bioabsorbable Stents Market by Material (Polymer/Metal), Absorption Rate (Slow, Fast), Application (Coronary Artery Disease/CAD, Peripheral/PAD) & End User (Hospital, Cardiovascular Center) - Global Forecasts to 2022
The global bioresorbable stents market is projected to reach USD 417.2 Million by 2022, at a CAGR of 11.5%. Market growth of bioresorbable stents is attributed to the growing aging population susceptible to coronary and peripheral artery diseases, rising PCI procedures, increasing focus of companies on clinical trials of bioresorbable stents, increasing adoption of these stents by physicians and patients, and patients’ preference for minimally invasive therapies. However, factors such as the increasing product withdrawals due to severe complications of these stents may hamper market growth. The bioresorbable stents screening market is a niche market with the presence of several emerging players and few big players. Prominent players in the market include Abbott (U.S.), BIOTRONIK SE & Co. KG (Germany), REVA Medical, Inc. (U.S.), Elixir Medical Corporation (U.S.), and Kyoto Medical Planning Co., Ltd. (Japan).
- Published: August 2017
- Price: $ 4950
- TOC Available:
-
Protein Assays Market by Product (Reagent, Kit, Instruments), Type (Dye Binding, Test Strip), Application (Drug Discovery, Disease Diagnosis), Technology (Colorimetric, Fluorescence), End User (Pharmaceutical, Clinical Lab) - Global Forecasts to 2022
The protein assays market is projected to reach USD 2.41 Billion by 2022, at a CAGR of 11.1%. Some of the prominent players in the market are Thermo Fisher Scientific (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Merck KGaA (Germany), Cell Signaling Technology, Inc. (U.S.), General Electric Company (U.S.), and PerkinElmer Inc. (U.S.).
- Published: May 2017
- Price: $ 4950
- TOC Available:
-
Asia Pacific Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)- Forecast to 2030
The Asia Pacific biomarkers Market, valued at US$13.51 billion in 2024, stood at US$14.73 billion in 2025 and is projected to advance at a resilient CAGR of 12.4% from 2025 to 2030, culminating in a forecasted valuation of US$26.40 billion by the end of the period. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response; this market includes consumables, services, and software used for biomarker-related research.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Gene Panel Market by Product & Service, Technique (Amplicon, Hybridization), Design (Predesign, Custom), Application (Cancer, Congenital Disease, Pharmacogenetics) & End User (Hospital, Research Center, Pharmaceutical Companies) - Global Forecasts to 2023
The global gene panel market is expected to reach USD 2.95 Billion by 2023, at a CAGR of 19.2%. The growth of this market is mainly driven by the increasing prevalence of chronic diseases, growing company initiatives, and rising adoption of gene panel owing to the benefits they offer. The gene panel market is fragmented, with the presence of several large as well as emerging players. Prominent players in the gene panels market include Illumina, Inc. (US), BGI (China), Agilent Technologies (US), Eurofins Scientific (US), QIAGEN (Germany), GENEWIZ, Inc. (US), Novogene Corporation (China), Personalis (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche AG (Switzerland), Integrated DNA Technologies (IDT) (US), GATC Biotech AG (GATC Biotech) (Germany), and ArcherDx (US). Players in this market are adopting various organic and inorganic strategies, such as product launches & upgradations, agreements, partnerships, joint ventures, collaborations, and acquisition to widen their product portfolios and expand their presence in the market.
- Published: May 2018
- Price: $ 4950
- TOC Available:
-
Predictive Clinical Biomarkers Market by Product & Service (Consumable, Software), Technology (NGS, PCR), Disease (Cancer, Infectious), Application (Clinical Diagnostics)-Forecast to 2030
The predictive clinical biomarkers market, valued at US$7.84 billion in 2024, stood at US$8.49 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2025 to 2030, culminating in a forecasted valuation of US$14.69 billion by the end of the period. he market for predictive clinical biomarkers is growing rapidly as the healthcare industry shifts toward personalized and predictive medicine.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Latin America In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Disease) - Forecast to 2031
The Latin America in vitro diagnostics (IVD) market, valued at USD 5.48 billion in 2025, stood at USD 5.87 billion in 2026 and is projected to advance at a resilient CAGR of 6.7% from 2026 to 2031, culminating in a forecasted valuation of USD 8.13 billion by the end of the period. The increasing demand for diagnostic services, along with the growing need for routine and specialized testing, is driving the market. Investments in lab infrastructure, combined with the adoption of automated and standardized diagnostic procedures, contribute to increasing test volumes in both the public and private healthcare sectors.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Sexually Transmitted Diseases Diagnostics Market by Disease Type (CT/NG, Gonorrhea, Syphilis, Genital Herpes, Hepatitis B, HIV/AIDS, HPV), End User (Laboratory, PoC) and Geography - Global Forecast to 2027
The STDs diagnostics market size is projected to reach $99,431.6 million by 2027 from $91,441.5 million in 2022, at a CAGR of 5.6% during the forecast period. Sexually transmitted diseases diagnostics market is driven by factors such as global prevalence of HIV, CT/NG, and other STDs and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements. On the other hand, an unfavorable reimbursement scenario is expected to limit market growth to a certain extent in the coming years.
- Published: July 2026
- Price: $ 4950
- TOC Available:
-
Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, Region - Global Forecast to 2028
The global antibody drug conjugates market, valued at US$7.6 billion in 2022, stood at US$9.7 billion in 2023 and is projected to advance at a resilient CAGR of 15.2% from 2025 to 2028, culminating in a forecasted valuation of US$19.8 billion by the end of the period. Growth in the market can be attributed to various factors such as including the growing prevalence of cancer, and increasing R&D activities for the development of novel ADCs by key market players.
- Published: October 2023
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
